Status:
UNKNOWN
Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury
Lead Sponsor:
Jingyuan,Xu
Conditions:
Evaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDS
Eligibility:
All Genders
18-80 years
Brief Summary
To observe the changes of plasma ESM-1 levels in patients with ARDS, and to explore its clinical significance.
Detailed Description
70 patients who diagnosed as ARDS were included in this study. Then keep blood samples from these patients in the first day, the third day and the seventh day, detect ESM-1 level in plasma by ELISA. R...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients admitted to ICU diagnosed of ARDS (Berlin definition）in 48h
- Patients age between 18 years old and 80 years.
- Exclusion Criteria：
- Pregnant women,
- Patients with malignant tumor,
- Immunosuppression or immunocompromised patients.
Exclusion
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 20 2018
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03296761
Start Date
November 1 2017
End Date
February 20 2018
Last Update
November 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing Zhongda Hospital, School of Medicine, Southeast University
Nanjing, Jiangsu, China, 210009